August 10, 2011
A New York federal judge refused Wednesday to dismiss a putative securities class action stemming from a $2.3 billion civil and criminal fine Pfizer Inc. paid for illegally marketing off-label uses of four drugs and offering doctors kickbacks to promote the medications.